Indian firms: Don't judge IP regime by 'isolated' cases
This article was originally published in Scrip
Executive Summary
Concerns against the 'India's intellectual property rights (IPR) regime voiced by part of the US pharmaceutical industry are ''overstated'' and ought to be viewed in the light of the ''overall record'' of patents granted and revoked in the country, say Indian firms.